Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke

被引:17
作者
Ha, Junghee [1 ]
Choi, Dong-Woo [7 ]
Kim, Kwang Joon [2 ,3 ]
Kim, Keun You [1 ,8 ]
Nam, Chung Mo [4 ,5 ]
Kim, Eosu [1 ,6 ]
机构
[1] Yonsei Univ, Dept Psychiat, Brain Korea FOUR Project Med Sci 21, Coll Med, Seoul, South Korea
[2] Yonsei Univ, Inst Behav Sci Med, Brain Korea FOUR Project Med Sci 21, Coll Med, Seoul, South Korea
[3] Yonsei Univ, Brain Korea FOUR Project Med Sci 21, Div Geriatr, Coll Med, Seoul, South Korea
[4] Yonsei Univ, Dept Internal Med, Brain Korea FOUR Project Med Sci 21, Coll Med, Seoul, South Korea
[5] Yonsei Univ, Dept Prevent Med, Brain Korea FOUR Project Med Sci 21, Coll Med, Seoul, South Korea
[6] Yonsei Univ, Grad Sch Med Sci, Brain Korea FOUR Project Med Sci 21, Coll Med, Seoul, South Korea
[7] Natl Canc Control Inst, Canc Big Data Ctr, Natl Canc Ctr, Gyeonggi Do, South Korea
[8] Seoul Natl Univ, Dept Psychiat, Seoul Metropolitan Govt, Boramae Med Ctr, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
ACTIVATED-RECEPTOR-GAMMA; ALZHEIMERS-DISEASE; INSULIN-RESISTANCE; MOUSE MODEL; ROSIGLITAZONE; EXPRESSION; MECHANISM; MONOCYTES; INCREASE; PYRUVATE;
D O I
10.1212/WNL.0000000000207069
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and ObjectivesPrevious studies have reported the protective effect of pioglitazone on dementia in patients with type 2 diabetes mellitus (DM). Recent studies have shown that pioglitazone also lowers the risk of primary and recurrent stroke. Understanding the characteristics of patients particularly associated with the benefits of pioglitazone would facilitate its personalized use by specifying subpopulations during routine clinical care. The aim of this study was to examine the effects of pioglitazone use on dementia in consideration of stroke occurrence.MethodsUsing nationwide longitudinal data of patients with DM from the Korean National Health Insurance Service DM cohort (2002-2017), we investigated the association of pioglitazone use with incident dementia in patients with new-onset type 2 DM. The heterogeneity of the treatment effect was examined using exploratory analyses. Using a multistate model, we assessed the extent to which incident stroke affects the association between pioglitazone use and dementia.ResultsPioglitazone use was associated with a reduced risk of dementia, compared with nonuse (adjusted hazard ratio [aHR] = 0.84, 95% CI 0.75-0.95); the risk reduction in dementia was greater among patients with a history of ischemic heart disease or stroke before DM onset (aHR = 0.46, 95% CI 0.24-0.90; aHR = 0.57, 95% CI 0.38-0.86, respectively). The incidence of stroke was also reduced by pioglitazone use (aHR = 0.81, 95% CI 0.66-1.00). However, when the stroke developed during the observation period of pioglitazone use, such lowered risk of dementia was not observed (aHR = 1.27, 95% CI 0.80-2.04).DiscussionPioglitazone use is associated with a lower risk of dementia in patients with DM, particularly in those with a history of stroke or ischemic heart disease, suggesting the possibility of applying a personalized approach when choosing pioglitazone to suppress dementia in patients with DM.
引用
收藏
页码:E1799 / E1811
页数:13
相关论文
共 49 条
  • [1] The low dose (7.5 mg/day) pioglitazone is beneficial to the improvement in metabolic parameters without weight gain and an increase of risk for heart failure
    Adachi, Hiroki
    Katsuyama, Hisayuki
    Yanai, Hidekatsu
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 227 : 247 - 248
  • [2] Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?
    Akter, Kawser
    Lanza, Emily A.
    Martin, Stephen A.
    Myronyuk, Natalie
    Rua, Melanie
    Raffa, Robert B.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 71 (03) : 365 - 376
  • [3] Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes
    Betteridge, DJ
    Vergès, B
    [J]. DIABETOLOGIA, 2005, 48 (12) : 2477 - 2481
  • [4] PPARγ activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties
    Bouhlel, M. Amine
    Derudas, Bruno
    Rigamonti, Elena
    Dievart, Rebecca
    Brozek, John
    Haulon, Stephan
    Zawadzki, Christophe
    Jude, Brigitte
    Torpier, Gerard
    Marx, Nikolaus
    Staels, Bart
    Chinetti-Gbaguidi, Giulia
    [J]. CELL METABOLISM, 2007, 6 (02) : 137 - 143
  • [5] Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial
    Burns, Daniel K.
    Alexander, Robert C.
    Welsh-Bohmer, Kathleen A.
    Culp, Meredith
    Chiang, Carl
    O'Neil, Janet
    Evans, Rebecca M.
    Harrigan, Patrick
    Plassman, Brenda L.
    Burke, James R.
    Wu, Jingtao
    Lutz, Michael W.
    Haneline, Stephen
    Schwarz, Adam J.
    Schneider, Lon S.
    Yaffe, Kristine
    Saunders, Ann M.
    Ratti, Emiliangelo
    [J]. LANCET NEUROLOGY, 2021, 20 (07) : 537 - 547
  • [6] Peroxisome proliferator-activated receptor γ induces a clearance mechanism for the amyloid-β peptide
    Camacho, IE
    Serneels, L
    Spittaels, K
    Merchiers, P
    Dominguez, D
    De Strooper, B
    [J]. JOURNAL OF NEUROSCIENCE, 2004, 24 (48) : 10908 - 10917
  • [7] Effects of pioglitazone on the incidence of dementia in patients with diabetes
    Chou, Ping-Song
    Ho, Bo-Lin
    Yang, Yuan-Han
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2017, 31 (06) : 1053 - 1057
  • [8] Regulation of β-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor α
    Combs, CK
    Bates, P
    Karlo, JC
    Landreth, GE
    [J]. NEUROCHEMISTRY INTERNATIONAL, 2001, 39 (5-6) : 449 - 457
  • [9] Landmark Analysis at the 25-Year Landmark Point
    Dafni, Urania
    [J]. CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2011, 4 (03) : 363 - U216
  • [10] Peroxisome proliferator-activated receptor γ thiazolidinedione agonists increase glucose metabolism in astrocytes
    Dello Russo, C
    Gavrilyuk, V
    Weinberg, G
    Almeida, A
    Bolanos, JP
    Palmer, J
    Pelligrino, D
    Galea, E
    Feinstein, DL
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (08) : 5828 - 5836